Enanta Pharmaceuticals Inc (FRA:9EP)
€ 11.1 +0.30 (+2.78%) Market Cap: 326.71 Mil Enterprise Value: 233.81 Mil PE Ratio: 0 PB Ratio: 3.23 GF Score: 58/100

Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 01:20PM GMT
Release Date Price: €39.4 (+2.60%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. Good morning. Thanks, everyone, for joining us for the annual JPMorgan Health Care Conference. I'm Eric Joseph, senior biotech analyst. And our next presenting company this morning is Enanta Pharmaceuticals.

And it's my pleasure to welcome and introduce CEO, Jay Luly, to tell us a little bit about the company. Just a programming note before I hand it over for the presentation. There will be a Q&A after the presentation. Please do feel free to submit questions by clicking the Ask a Question button, and we'll ask on your behalf.

So with that, Jay, thanks, again, for sharing some of your time with us this morning.

Jay R. Luly
Enanta Pharmaceuticals, Inc. - President, CEO & Director

Well, thank you, and thank you for hosting this virtual meeting. I guess I'm driving the slides, and everybody is driving the slides at their end. So I want to remind you that I'll be making some forward-looking statements today. For a summary of the risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot